Quest Diagnostics Incorporated Stock News

Investors are optimistic about Quest Diagnostics (DGX) on strong legacy business growth.

Quest Diagnostics' (DGX) latest transaction combines its oncology expertise and scale with PathAI's AI and digital pathology innovations.

WASHINGTON — Makers of medical tests that have long escaped government oversight will have about four years to show that their new offerings deliver accurate results, under a government rule vigorou

Quest Diagnostics (DGX) continues its strong momentum of base business revenue growth in the first quarter of 2024.

Quest Diagnostics (DGX) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $1.86 per share. This compares to earnings of $2.04 per share a year ago.

Laboratory operator Quest Diagnostic raised its 2024 profit and revenue forecast on Tuesday after beating first-quarter estimates on robust demand for its diagnostic tests.

Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Acquisitions and partnerships with health plans are expected to drive Quest Diagnostics' (DGX) base business performance in the first quarter of 2024.

Quest Diagnostics (DGX) collaboration is intended to demonstrate the clinical value of WGS as a first-line genetic test for postnatal diagnosis of developmental delay disorders.

A list of top stocks expected to raise dividends in the upcoming week, with increases averaging 8.4% and median 6.8%. Companies included in the list have consistently grown their dividends for at leas

SECAUCUS, N.J., March 19, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report first quarter 2024 financial resul

Quest Diagnostics' (DGX) recent collaboration aims to advance food access and healthy eating habits for underserved communities.

SECAUCUS, N.J. , Feb. 23, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President and Chief Fi

Quest Diagnostics (DGX) debuts the MelaNodal Predict test in collaboration with SkylineDx.

Quest Diagnostics (DGX) introduces the first consumer-initiated blood test with physician consult on questhealth.com.